Abstract
Abstract
Purpose
Crohn’s disease (CD) is a progressive disorder leading to cumulative bowel damage. The Lémann index is a validated tool that can help in monitoring the progression of the disease and evaluating the effectiveness of different therapies. Our aim was to describe the main radiological findings in incidentally diagnosed CD and to evaluate bowel damage in this subgroup compared to patients diagnosed at later stages.
Methods
Patients with an incidental diagnosis of CD during the colorectal cancer screening program were compared to controls with a CD cohort diagnosed after symptomatic onset and matched 1:1 by disease extent. All cross-sectional examinations were centrally read, performing a descriptive analysis of the main findings and calculation of Lémann index.
Results
Thirty-eight patients were included: 19 with preclinical CD (median age 55 years (IQR, 54–62), 53% male, 74% non-smokers; 74% B1 and 26% B2) and 19 matched-controls with symptomatic CD. In those with preclinical CD, the most frequent transmural findings on MRE were contrast enhancement (79%), wall thickening (79%), followed by lymphadenopathy (68%), edema (42%), and increased vascularity (42%). Among those with strictures, controls showed a higher rate of preestenotic dilation (100% vs. 0%, p = 0.01). Bowel damage assessment revealed no statistically significant differences in the Lémann index between preclinical CD and controls (p = 0.95). A statistically significant higher score in the colonic/rectum score was observed (p = 0.014).
Conclusion
Patients with preclinical CD demonstrate similar radiological findings and degree of bowel damage as new-onset symptomatic CD.
Funder
Gobierno Vasco – Eusko Jaurlaritza
Biocruces Bizkaia HRI
Universidad de Deusto
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Collaborators GBDIBD (2020) The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol 5(1):17–30
2. Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A et al (2020) Crohn’s disease. Nat Rev Dis Primers 6(1):22
3. Iglesias-Rey M, Barreiro-de Acosta M, Caamano-Isorna F, Rodriguez IV, Ferreiro R, Lindkvist B et al (2014) Psychological factors are associated with changes in the health-related quality of life in inflammatory bowel disease. Inflamm Bowel Dis 20(1):92–102
4. Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V et al (2019) Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 68(3):423–433
5. Chaparro M, Garre A, Nunez Ortiz A, Diz-Lois Palomares MT, Rodriguez C, Riestra S et al (2021) Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study. J Clin Med 10(13):2885